Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

UBS Ups JNJ Price Target to $320 Amid Improved Outlook

Guavy AI Editorial Team
Instruments
JNJ
Share

UBS has raised its price target for Johnson & Johnson shares to $320 from $280, maintaining a Buy rating on the stock. This increase represents a $40 jump from the firm's previous target for the healthcare company.

The current stock price stands at $271.19, which is near the 52-week high of $276.47. According to InvestingPro analysis, JNJ appears overvalued at current levels.

UBS analyst Michael Yee issued the updated price target for Johnson & Johnson.

More on Stocks

Stocks just now

Egypt Teams Up with Cisco for AI Infrastructure and Skills Training Push

Stocks just now

Getafe City Council Criticizes Iberdrola Music Venue Mobility Chaos

Stocks 2m ago

Universal Nights at Epic Universe Adds More Dates

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy